Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Nov 1, 2026.

International Consensus (ICON): allergic reactions to vaccines

Stephen C. Dreskin, Neal A. Halsey, John M. Kelso and 13 more

World Allergy Organization Journal · 2016

doi:10.1186/s40413-016-0120-5

Abstract

BACKGROUND: Routine immunization, one of the most effective public health interventions, has effectively reduced death and morbidity due to a variety of infectious diseases. However, allergic reactions to vaccines occur very rarely and can be life threatening. Given the large numbers of vaccines administered worldwide, there is a need for an international consensus regarding the evaluation and management of allergic reactions to vaccines. METHODS: Following a review of the literature, and with the active participation of representatives from the World Allergy Organization (WAO), the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI), the final committee was formed with the purpose of having members who represented a wide-range of countries, had previously worked on vaccine safety, and included both allergist/immunologists as well as vaccinologists. RESULTS: Consensus was reached on a variety of topics, including: definition of immediate allergic reactions, including anaphylaxis, approaches to distinguish association from causality, approaches to patients with a history of an allergic reaction to a previous vaccine, and approaches to patients with a history of an allergic reaction to components of vaccines. CONCLUSIONS: This document provides comprehensive and internationally accepted guidelines and access to on-line documents to help practitioners around the world identify allergic reactions following immunization. It also provides a framework for the evaluation and further management of patients who present either following an allergic reaction to a vaccine or with a history of allergy to a component of vaccines.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 176

  1. 1.
    Vaccines for the 21st century · 2014
    No notice
  2. 2.

    Whitney CG, Zhou FJ, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era - United States, 1994–2013. Mmwr-Morbid Mortal W. 2014;63(16):352-5.

    Not in our library

  3. 3.

    Caubet JC, Ponvert C. Vaccine allergy. Immunol Allergy Clin North Am. 2014;34(3):597-613.

    Not in our library10.1016/j.iac.2014.04.004

  4. 4.

    Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43.

    Not in our library10.1016/j.jaci.2012.04.003

  5. 5.

    Vanlander A, Hoppenbrouwers K. Anaphylaxis after vaccination of children: review of literature and recommendations for vaccination in child and school health services in Belgium. Vaccine. 2014;32(26):3147-54.

    Not in our library10.1016/j.vaccine.2014.03.096

  6. 6.

    Wood RA. Allergic reactions to vaccines. Pediatr Allergy Immunol. 2013;24(6):521-6.

    Not in our library10.1111/pai.12102

  7. 7.

    RedBook. Red Book 2015: Report of the Committee on Infectious Diseases 30 ed. American Academy of Pediatrics; 2015.

    Not in our library

  8. 8.

    Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-20.

    Not in our library10.1542/peds.112.4.815

  9. 9.

    Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations--a post-marketing surveillance review. Eur J Pediatr. 2002;161(1):21-5.

    Not in our library10.1007/s00431-001-0853-0

  10. 10.

    Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child. 2012;97(6):487-90.

    Not in our library10.1136/archdischild-2011-301163

  11. 11.

    Cheng DR, Perrett KP, Choo S, Danchin M, Buttery JP, Crawford NW. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Vaccine. 2015;33(13):1602-7.

    Not in our library10.1016/j.vaccine.2015.02.008

  12. 12.

    Lotvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We call for iCAALL: International Collaboration for Asthma, Allergy and Immunology. Ann Allergy Asthma Immunol. 2012;108(4):215-6.

    Not in our library10.1016/j.anai.2012.02.025

  13. 13.

    Lotvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. J Allergy Clin Immunol. 2012;129(4):904-5.

    Not in our library10.1016/j.jaci.2012.02.009

  14. 14.

    Lotvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We call for iCAALL: International Collaboration in Asthma. Allergy Immunol Allergy. 2012;67(4):449-50.

    Not in our library10.1111/j.1398-9995.2012.02813.x

  15. 15.

    Lotvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We Call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. World Allergy Organ J. 2012;5(3):39-40.

    Not in our library10.1097/wox.0b013e3182504245

  16. 16.

    Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization. MMWR Recomm Rep. 2011;60(2):1-64.

    Not in our library

  17. 17.

    Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813-24.

    Not in our library10.1034/j.1398-9995.2001.t01-1-00001.x

  18. 18.
    International consensus on (ICON) anaphylaxis · 2014
    No notice
  19. 19.

    Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-7.

    Not in our library10.1016/j.jaci.2005.12.1303

  20. 20.

    Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675-84.

    Not in our library10.1016/j.vaccine.2007.02.064

  21. 21.

    Simons FE, Sampson HA. Anaphylaxis: Unique aspects of clinical diagnosis and management in infants (birth to age 2 years). J Allergy Clin Immunol. 2015;135(5):1125-31.

    Not in our library10.1016/j.jaci.2014.09.014

  22. 22.

    Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. 2008;122(6):1166-8.

    Not in our library10.1016/j.jaci.2008.10.019

  23. 23.

    Simons FE. Anaphylaxis pathogenesis and treatment. Allergy. 2011;66(Suppl 95):31-4.

    Not in our library10.1111/j.1398-9995.2011.02629.x

  24. 24.

    Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics. 2000;106(4):762-6.

    Not in our library10.1542/peds.106.4.762

  25. 25.

    Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95(3):217-26.

    Not in our library10.1016/s1081-1206(10)61217-3

  26. 26.

    Vinuya RZ, Simon MR, Schwartz LB. Elevated serum tryptase levels in a patient with protracted anaphylaxis. Ann Allergy. 1994;73(3):232-4.

    Not in our library

  27. 27.

    Muraro A, Roberts G, Worm M, Bilo MB, Brockow K, Fernandez Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026-45.

    Not in our library10.1111/all.12437

  28. 28.

    Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30(8):1144-50.

    Not in our library10.1046/j.1365-2222.2000.00864.x

  29. 29.

    Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-80 e1-42.

    Not in our library10.1016/j.jaci.2010.06.022

  30. 30.

    Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315-24.

    Not in our library10.1111/j.1572-0241.2003.07457.x

  31. 31.

    Brown SGA, Kemp SF, Lieberman PL, Adkinson NF, Bochner BS. Anaphylaxis. Middleton's Allergy: Principles and Practice. 2014;1237-59.

    Not in our library

  32. 32.

    Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2007;25(31):5875-81.

    Not in our library10.1016/j.vaccine.2007.04.061

  33. 33.

    Centers for Disease C, Prevention. Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457-60.

    Not in our library

  34. 34.

    Statement regarding interim findings of WHO assessment of deaths of children in Idleb Governorate, Syria. http://www.emro.who.int/entity/vpi/index.html. Accessed Aug 2016.

    Not in our library

  35. 35.

    Sood DK, Kumar S, Singh S, Sokhey J. Adverse reactions after measles vaccination in India. Natl Med J India. 1995;8(5):208-10.

    Not in our library

  36. 36.

    Orr P. Supplementary statement for the 2002–2003 influenza season: update on oculo-respiratory syndrome in association with influenza vaccination. Can Commun Dis Rep. 2002;28(ACS-6):1.

    Not in our library

  37. 37.

    De Serres G, Toth E, Menard S, Grenier JL, Roussel R, Tremblay M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine. 2005;23(28):3726-32.

    Not in our library10.1016/j.vaccine.2005.01.154

  38. 38.

    Skowronski DM, Strauss B, De Serres G, MacDonald D, Marion SA, Naus M, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis. 2003;36(6):705-13.

    Not in our library10.1086/367667

  39. 39.

    Stratton KR, Howe CI, Johnston RB. Adverse events associated with childhood vaccines: evidence bearing on causality. 1994.

    Not in our library

  40. 40.

    Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B, Brighton Collaboration Working Group on A. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010;28(28):4487-98.

    Not in our library10.1016/j.vaccine.2010.04.041

  41. 41.

    Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589-96.

    Not in our library10.1016/j.jaci.2014.12.1947

  42. 42.

    Pinson ML, Waibel KH. Safe administration of a gelatin-containing vaccine in an adult with galactose-alpha-1,3-galactose allergy. Vaccine. 2015;33(10):1231-2.

    Not in our library10.1016/j.vaccine.2015.01.020

  43. 43.

    Kelso JM. Allergic reactions after immunization. Ann Allergy Asthma Immunol. 2013;110(6):397-401.

    Not in our library10.1016/j.anai.2013.03.001

  44. 44.

    Anonymous. CDC: Possible side effects of vaccines. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm. Accessed Aug 2016.

    Not in our library

  45. 45.

    Anonymous. WHO: Adverse Events Following Vaccines. http://www.who.int/vaccine_safety/initiative/detection/en/. Accessed Aug 2016.

    Not in our library

  46. 46.

    Halsey NA. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis. 2002;13(3):205-14.

    Not in our library10.1053/spid.2002.125864

  47. 47.

    Halsey NA, Edwards KM, Dekker CL, Klein NP, Baxter R, Larussa P, et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine. 2012;30(39):5791-8.

    Not in our library10.1016/j.vaccine.2012.04.005

  48. 48.

    Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013;31(44):5041-6.

    Not in our library10.1016/j.vaccine.2013.08.087

  49. 49.

    Stratton K, Ford A, Rusch E, Clayton EW. Adverse Effects of Vaccines: Evidence and Causality. 2012.

    Not in our library

  50. 50.

    Brighton Collaboration Anaphylaxis Working G. https://brightoncollaboration.org/public/what-we-do/setting-standards/case-definitions/available-definitions.html. Accessed Aug 2016.

    Not in our library

  51. 51.

    Jackson LA, Yu O, Nelson JC, Dominguez C, Peterson D, Baxter R, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics. 2011;127(3):e581-7.

    Not in our library10.1542/peds.2010-1886

  52. 52.

    Beveridge MG, Polcari IC, Burns JL, Adler A, Hendrickson B, Stein SL. Local vaccine site reactions and contact allergy to aluminum. Pediatr Dermatol. 2012;29(1):68-72.

    Not in our library10.1111/j.1525-1470.2011.01541.x

  53. 53.

    Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr. 2013;172(2):171-7.

    Not in our library10.1007/s00431-012-1841-2

  54. 54.

    Jackson LA, Carste BA, Malais D, Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J. 2002;21(8):781-6.

    Not in our library10.1097/00006454-200208000-00016

  55. 55.

    Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol. 1999;103(2 Pt 1):321-5.

    Not in our library10.1016/s0091-6749(99)70508-7

  56. 56.

    Nakayama T, Aizawa, C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol. 2000; 106:591-592.

    Not in our library10.1067/mai.2000.108433

  57. 57.

    Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2002;110(6).

    Not in our library10.1542/peds.110.6.e71

  58. 58.

    King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine. 2009;27(47):6589-94.

    Not in our library10.1016/j.vaccine.2009.08.032

  59. 59.

    Seqirus, Inc. Flucelvax package insert. Holly Springs: Seqirus, Inc.; 2012. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM329134.pdf. Accessed Aug 2016.

    Not in our library

  60. 60.

    Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014;134(2):325-37.

    Not in our library10.1542/peds.2014-1079

  61. 61.

    Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine. 2013;31(51):6107-12.

    Not in our library10.1016/j.vaccine.2013.09.066

  62. 62.

    Kawai AT, Li L, Kulldorff M, Vellozzi C, Weintraub E, Baxter R, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012–2013 season. Pharmacoepidemiol Drug Saf. 2014;23(5):548-53.

    Not in our library10.1002/pds.3575

  63. 63.

    Ropero-Alvarez AM, Whittembury A, Bravo-Alcantara P, Kurtis HJ, Danovaro-Holliday MC, Velandia-Gonzalez M. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean. Vaccine. 2015;33(1):187-92.

    Not in our library10.1016/j.vaccine.2014.10.070

  64. 64.

    Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol. 2010;126(2):317-23.

    Not in our library10.1016/j.jaci.2010.05.037

  65. 65.

    Schuler JE, King WJ, Dayneka NL, Rastelli L, Marquis E, Chad Z, et al. Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease. Can J Public Health. 2011;102(3):196-9.

    Not in our library10.1007/bf03404895

  66. 66.

    Vasu N, Ghaffari G, Craig ET, Craig TJ. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis. 2008;2(4):193-8.

    Not in our library10.1177/1753465808093933

  67. 67.

    Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy Asthma Immunol. 2005;94(1):90-4.

    Not in our library10.1016/s1081-1206(10)61292-6

  68. 68.

    Rouleau I, De Serres G, Drolet JP, Banerjee D, Lemire C, Moore A, et al. Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. J Allergy Clin Immunol. 2012;130(6):1423-6.

    Not in our library10.1016/j.jaci.2012.07.019

  69. 69.

    Anonymous. Statement on Seasonal Influenza Vaccine for 2015–2016. In:An Advisory Committee Statement (ACS). Publick Health Agency of Canada. 2015. http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php. Accessed Aug 2016.

    Not in our library

  70. 70.

    Carapetis JR, Curtis N, Royle J. MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare. BMJ. 2001;323(7317):869.

    Not in our library10.1136/bmj.323.7317.869a

  71. 71.

    Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. Biologicals. 2003;31(4):245-9.

    Not in our library10.1016/s1045-1056(03)00063-0

  72. 72.

    D'Souza RM, Campbell-Lloyd S, Isaacs D, Gold M, Burgess M, Turnbull F, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell. 2000;24(2):27-33.

    Not in our library10.33321/cdi.2000.24.4

  73. 73.

    Bruno G, Giampietro PG, Grandolfo ME, Milita O, Businco L. Safety of measles immunisation in children with IgE-mediated egg allergy. Lancet. 1990;335(8691):739.

    Not in our library10.1016/0140-6736(90)90863-z

  74. 74.

    Khakoo GA, Lack G. Recommendations for using MMR vaccine in children allergic to eggs. BMJ. 2000;320(7239):929-32.

    Not in our library10.1136/bmj.320.7239.929

  75. 75.

    Esteghamati A, Keshtkar A, Heshmat R, Gouya MM, Salar Amoli M, Armin S, et al. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. Arch Iran Med. 2011;14(2):91-5.

    Not in our library

  76. 76.

    Andersen DV, Jorgensen IM. MMR vaccination of children with egg allergy is safe. Dan Med J. 2013;60(2):A4573.

    Not in our library

  77. 77.

    Fina Aviles F, Campins Marti M, Martinez Gomez X, Rodrigo Pendas JA, Lushchenkova O, Pimos Tella L, et al. MMR vaccine and egg allergy. Experience in a hospital immunization unit. An Pediatr (Barc). 2007;67(4):362-7.

    Not in our library10.1016/s1695-4033(07)70654-9

  78. 78.

    Patja A, Makinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics. 2001;107(2).

    Not in our library10.1542/peds.107.2.e27

  79. 79.

    Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr. 1992;120(6):878-81.

    Not in our library10.1016/s0022-3476(05)81953-5

  80. 80.

    James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995;332(19):1262-6.

    Not in our library10.1056/nejm199505113321904

  81. 81.

    Cronin J, Scorr A, Russell S, McCoy S, Walsh S, O'Sullivan R. A review of a paediatric emergency department vaccination programme for patients at risk of allergy/anaphylaxis. Acta Paediatr. 2012;101(9):941-5.

    Not in our library10.1111/j.1651-2227.2012.02737.x

  82. 82.

    Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19(7–8):916-23.

    Not in our library10.1016/s0264-410x(00)00297-8

  83. 83.

    Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000;284(10):1271-9.

    Not in our library10.1001/jama.284.10.1271

  84. 84.

    Sakaguchi M, Yamanaka T, Ikeda K, Sano Y, Fujita H, Miura T, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol. 1997;99(2):263-4.

    Not in our library10.1016/s0091-6749(97)70108-8

  85. 85.

    Sakaguchi M, Inouye S. Systemic allergic reactions to gelatin included in vaccines as a stabilizer. Jpn J Infect Dis. 2000;53(5):189-95.

    Not in our library

  86. 86.

    Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine. 2005;23(10):1205-8.

    Not in our library10.1016/j.vaccine.2004.08.040

  87. 87.

    Rabe IB, Miller ER, Fischer M, Hills SL. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012. Vaccine. 2015;33(5):708-12.

    Not in our library10.1016/j.vaccine.2014.11.046

  88. 88.

    Intercell. JE-VC Package Insert. Intercell Biomedical (Unitred Kingdom). 2013.

    Not in our library

  89. 89.

    Bollinger ME, Hamilton RG, Wood RA. Protamine allergy as a complication of insulin hypersensitivity: a case report. J Allergy Clin Immunol. 1999;104(2 Pt 1):462-5.

    Not in our library10.1016/s0091-6749(99)70394-5

  90. 90.

    Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung. 1999;28(6):418-28.

    Not in our library10.1016/s0147-9563(99)70031-2

  91. 91.

    Dobardzic A, Izurieta H, Woo EJ, Iskander J, Shadomy S, Rupprecht C, et al. Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997–2005. Vaccine. 2007;25(21):4244-51.

    Not in our library10.1016/j.vaccine.2007.02.075

  92. 92.

    Majchrowicz H. Post-vaccination reactions to diploid rabies vaccine. Przegl Epidemiol. 1989;43(3):259-62.

    Not in our library

  93. 93.

    Haditsch M, Kunze U. Tick-borne encephalitis: a disease neglected by travel medicine. Travel Med Infect Dis. 2013;11(5):295-300.

    Not in our library10.1016/j.tmaid.2013.07.003

  94. 94.

    Suss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview. Ticks Tick Borne Dis. 2011;2(1):2-15.

    Not in our library10.1016/j.ttbdis.2010.10.007

  95. 95.

    Bogovic P, Strle F. Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management. World J Clin Cases. 2015;3(5):430-41.

    Not in our library10.12998/wjcc.v3.i5.430

  96. 96.

    Zent O, Beran J, Jilg W, Mach T, Banzhoff A. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine. 2003;21(7–8):738-41.

    Not in our library10.1016/s0264-410x(02)00592-3

  97. 97.

    Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine. 2006;24(24):5256-63.

    Not in our library10.1016/j.vaccine.2006.03.061

  98. 98.

    Canadian Immunization Guide. 2015. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/acs-03/index-eng.php.

    Not in our library

  99. 99.

    Arroabarren E, Anda M, Sanz ML. Anaphylaxis to pneumococcal vaccine; CRM(197): novel cause of vaccine allergy. Pediatr Allergy Immunol. 2016;27(4):433-7.

    Not in our library10.1111/pai.12548

  100. 100.

    Nelson MR, Oaks H, Smith LJ, Engler RJ. Anaphylaxis complicating routine childhood immunization: hemophilus influenza b conjugated vaccine. Pediatric Asthma, Allergy & Immunology. 2000;14(4):315-21.

    Not in our library10.1089/088318700750070411

  101. 101.

    Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014;3(1):50-7.

    Not in our library10.7774/cevr.2014.3.1.50

  102. 102.

    Finn TM, Egan W, Plotkin S, Orenstein WA, Offit P. Vaccine additives and manufacturing residuals in United States licensed vaccines. Vaccines. 2008;73-81.

    Not in our library

  103. 103.

    Anonymous. Allergens in Vaccines. Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Publick Health. 2015. http://www.vaccinesafety.edu/components-Allergens.htm. Accessed Aug 2016.

    Not in our library

  104. 104.

    Bergfors E, Hermansson G, Nystrom Kronander U, Falk L, Valter L, Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr. 2014;173(10):1297-307.

    Not in our library10.1007/s00431-014-2318-2

  105. 105.

    Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B. Unexpected loss of contact allergy to aluminium induced by vaccine. Contact Dermatitis. 2013;68(5):286-92.

    Not in our library10.1111/cod.12053

  106. 106.

    Chong H, Brady K, Metze D, Calonje E. Persistent nodules at injection sites (aluminium granuloma) -- clinicopathological study of 14 cases with a diverse range of histological reaction patterns. Histopathology. 2006;48(2):182-8.

    Not in our library10.1111/j.1365-2559.2005.02312.x

  107. 107.

    Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth E, et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine. 2013;31(50):5989-96.

    Not in our library10.1016/j.vaccine.2013.10.033

  108. 108.

    Rouleau I, De Serres G, Skowronski DM, Drolet JP, Lemire C, Toth E, et al. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine. 2014;32(28):3480-7.

    Not in our library10.1016/j.vaccine.2014.04.059

  109. 109.

    Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016;34(6):714-22.

    Not in our library10.1016/j.vaccine.2015.12.024

  110. 110.

    Seqirus I. FLUAD, Package Insert. 2016.

    Not in our library

  111. 111.

    Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity--update and overview. Swiss Med Wkly. 2010;140(17–18):238-46.

    Not in our library10.4414/smw.2010.12980

  112. 112.

    Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity reactions to vaccine constituents: a case series and review of the literature. Dermatitis. 2012;23(3):102-9.

    Not in our library10.1097/der.0b013e31825228cf

  113. 113.

    Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007;99(6):574-5.

    Not in our library10.1016/s1081-1206(10)60391-2

  114. 114.

    Lear JT, English JS. Anaphylaxis after hepatitis B vaccination. Lancet. 1995;345(8959):1249.

    Not in our library10.1016/s0140-6736(95)92039-0

  115. 115.

    Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2004;23(5):664-7.

    Not in our library10.1016/j.vaccine.2004.06.042

  116. 116.

    Hamborsky J, Kroger A, Wolfe C. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. The Pink Book. Washington, DC: Centers for Disease Control and Prevention; Public Health Foundation; 2015. Also, http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf. Accessed Aug 2016.

    Not in our library

  117. 117.

    Kelso JM. Safety of influenza vaccines. Curr Opin Allergy Clin Immunol. 2012;12(4):383-8.

    Not in our library10.1097/aci.0b013e328354395d

  118. 118.

    Kelso JM, Li JT, Nicklas RA, Blessing-Moore J, Cox L, Lang DM, et al. Adverse reactions to vaccines. Ann Allergy Asthma Immunol. 2009;103(4 Suppl 2):S1-14.

    Not in our library10.1016/s1081-1206(10)60350-x

  119. 119.

    Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3):e771-7.

    Not in our library10.1542/peds.2008-1002

  120. 120.

    Caubet JC, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Managing a child with possible allergy to vaccine. Pediatr Allergy Immunol. 2014;25(4):394-403.

    Not in our library10.1111/pai.12132

  121. 121.

    Ponvert C, Ardelean-Jaby D, Colin-Gorski AM, Soufflet B, Hamberger C, de Blic J, et al. Anaphylaxis to the 23-valent pneumococcal vaccine in child: a case–control study based on immediate responses in skin tests and specific IgE determination. Vaccine. 2001;19(32):4588-91.

    Not in our library10.1016/s0264-410x(01)00257-2

  122. 122.

    Wood RA, Setse R, Halsey N, Clinical Immunization Safety Assessment Network Hypersensitivity Working G. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478-81.

    Not in our library10.1016/j.jaci.2007.04.035

  123. 123.

    Ponvert C. Allergic and non-allergic hypersensitivity reactions to toxoid-containing vaccines. Arch Pediatr. 2009;16(4):391-5.

    Not in our library10.1016/j.arcped.2009.01.002

  124. 124.

    Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(32):691-7.

    Not in our library

  125. 125.

    Kelso JM. Raw egg allergy-a potential issue in vaccine allergy. J Allergy Clin Immunol. 2000;106(5):990.

    Not in our library10.1067/mai.2000.110800

  126. 126.

    Merck & Co. I. M-M-R II Package Insert. Merck & Co., Inc.; 2014. Also, https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf. Accessed Aug 2016.

    Not in our library

  127. 127.

    Novartis, Inc. RabAvert package insert. Basil: Novartis, Inc; 2013.Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM312931.pdf. Accessed Aug 2016.

    Not in our library

  128. 128.

    Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr. 1983;102(2):196-9.

    Not in our library10.1016/s0022-3476(83)80519-8

  129. 129.

    O'Brien TC, Maloney CJ, Tauraso NM. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. Appl Microbiol. 1971;21(4):780-2.

    Not in our library10.1128/am.21.4.780-782.1971

  130. 130.

    Kelso JM. Administering influenza vaccine to egg-allergic persons. Expert Rev Vaccines. 2014;13(8):1049-57.

    Not in our library10.1586/14760584.2014.933079

  131. 131.

    Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine. 1996;14(2):131-4.

    Not in our library10.1016/0264-410x(95)00154-s

  132. 132.

    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease C, Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34.

    Not in our library

  133. 133.

    Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.

    Not in our library

  134. 134.

    Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011;41(2):121-8.

    Not in our library10.1016/j.amepre.2011.04.004

  135. 135.

    Tavares F, Delaigle A, Slavin D, Bauchau V, Fries L, Seifert H. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine. 2011;29(37):6402-7.

    Not in our library10.1016/j.vaccine.2011.04.026

  136. 136.

    Woo EJ. Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis. 2015;60(5):777-80.

    Not in our library10.1093/cid/ciu948

  137. 137.

    Anonymous. European pharmacopia, 5.8 CD, 7/2007. Strasbourg, France: Euorpiean Directoriate for the Quality of Medicines and Health Care; 2007.

    Not in our library

  138. 138.

    Vajo Z, Tamas F, Jankovics I. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. Clin Vaccine Immunol. 2012;19(3):313-8.

    Not in our library10.1128/cvi.05619-11

  139. 139.

    Kelso JM, Greenhawt MJ, Li JT, Joint Task Force on Practice P. Update on influenza vaccination of egg allergic patients. Ann Allergy Asthma Immunol. 2013;111(4):301-2.

    Not in our library10.1016/j.anai.2013.07.030

  140. 140.

    Des Roches A, Samaan K, Graham F, Lacombe-Barrios J, Paradis J, Paradis L, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol In practice. 2015;3(1):138-9.

    Not in our library10.1016/j.jaip.2014.08.008

  141. 141.

    Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Investigators S-S. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. 2015;351:h6291.

    Not in our library10.1136/bmj.h6291

  142. 142.

    Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Investigators SS. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015.

    Not in our library10.1016/j.jaci.2014.12.1925

  143. 143.

    Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–2016 Influenza Season. Centers for Disease Control and Prevention. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm?s_cid=mm6430a3_e. Accessed Aug 2016.

    Not in our library

  144. 144.

    SanofiPasteur. YF-VAX Package Insert. Sanofi Pasteur; Lyon, France. 2013. Also, https://www.vaccineshoppe.com/image.cfm?doc_id=13709&image_type=product_pdf. Accessed Aug 2016.

    Not in our library

  145. 145.

    Kelso JM, Cockrell GE, Helm RM, Burks AW. Common allergens in avian meats. J Allergy Clin Immunol. 1999;104(1):202-4.

    Not in our library10.1016/s0091-6749(99)70136-3

  146. 146.

    Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 1999;103(4):698-701.

    Not in our library10.1016/s0091-6749(99)70245-9

  147. 147.

    Munoz-Cano R, Sanchez-Lopez J, Bartra J, Valero A. Yellow fever vaccine and egg allergy: really a problem? Allergy. 2010;65(4):533-4.

    Not in our library10.1111/j.1398-9995.2009.02205.x

  148. 148.

    Rutkowski K, Ewan PW, Nasser SM. Administration of yellow fever vaccine in patients with egg allergy. Int Arch Allergy Immunol. 2013;161(3):274-8.

    Not in our library10.1159/000346350

  149. 149.

    Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol. 1996;98(6 Pt 1):1058-61.

    Not in our library10.1016/s0091-6749(96)80191-6

  150. 150.

    Sakai Y, Yamato R, Onuma M, Kikuta T, Watanabe M, Nakayama T. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull. 1998;21(4):330-4.

    Not in our library10.1248/bpb.21.330

  151. 151.

    Bogdanovic J, Halsey NA, Wood RA, Hamilton RG. Bovine and porcine gelatin sensitivity in children sensitized to milk and meat. J Allergy Clin Immunol. 2009;124(5):1108-10.

    Not in our library10.1016/j.jaci.2009.06.021

  152. 152.

    Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol. 1993;91(4):867-72.

    Not in our library10.1016/0091-6749(93)90344-f

  153. 153.

    Kumagai T, Yamanaka T, Wataya Y, Umetsu A, Kawamura N, Ikeda K, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol. 1997;100(1):130-4.

    Not in our library10.1016/s0091-6749(97)70204-5

  154. 154.

    Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol. 1995;96(4):563-5.

    Not in our library10.1016/s0091-6749(95)70304-7

  155. 155.

    Singer S, Johnson CE, Mohr R, Holowecky C. Urticaria following varicella vaccine associated with gelatin allergy. Vaccine. 1999;17(4):327-9.

    Not in our library10.1016/s0264-410x(98)00209-6

  156. 156.

    Sakaguchi M, Yoshida M, Kuroda W, Harayama O, Matsunaga Y, Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine. 1997;15(2):121-2.

    Not in our library10.1016/s0264-410x(96)00170-3

  157. 157.

    Worm M, Sterry W, Zuberbier T. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Derm Venereol. 2000;80(3):232.

    Not in our library10.1080/000155500750043186

  158. 158.

    Nagel G, Hennig R, Broker M. New gelatine-free TBE vaccines with improved safety profile. Klin Padiatr. 2006;218(6):379.

    Not in our library10.1055/s-2006-942201

  159. 159.

    Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol. 2000;106(3):591-2.

    Not in our library10.1067/mai.2000.108433

  160. 160.

    Kattan JD, Konstantinou GN, Cox AL, Nowak-Wegrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol. 2011;128(1):215-8.

    Not in our library10.1016/j.jaci.2011.04.046

  161. 161.

    Parisi CA, Smaldini PL, Gervasoni ME, Maspero JF, Docena GH. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Exp Allergy. 2013;43(2):249-54.

    Not in our library10.1111/cea.12059

  162. 162.

    Kelso JM. Potential food allergens in medications. J Allergy Clin Immunol. 2014;133(6):1509-18.

    Not in our library10.1016/j.jaci.2014.03.011

  163. 163.

    Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol. 2011;128(2):434.

    Not in our library10.1016/j.jaci.2011.06.028

  164. 164.

    Quirce S, Diaz-Perales A. Diagnosis and management of grain-induced asthma. Allergy, Asthma Immunol Res. 2013;5(6):348-56.

    Not in our library10.4168/aair.2013.5.6.348

  165. 165.

    Baur X, Degens PO, Sander I. Baker's asthma: still among the most frequent occupational respiratory disorders. J Allergy Clin Immunol. 1998;102(6 Pt 1):984-97.

    Not in our library10.1016/s0091-6749(98)70337-9

  166. 166.

    Belchi-Hernandez J, Mora-Gonzalez A, Iniesta-Perez J. Baker's asthma caused by Saccharomyces cerevisiae in dry powder form. J Allergy Clin Immunol. 1996;97(1 Pt 1):131-4.

    Not in our library10.1016/s0091-6749(96)70293-2

  167. 167.

    Airola K, Petman L, Makinen-Kiljunen S. Clustered sensitivity to fungi: anaphylactic reactions caused by ingestive allergy to yeasts. Ann Allergy Asthma Immunol. 2006;97(3):294-7.

    Not in our library10.1016/s1081-1206(10)60792-2

  168. 168.

    Bielory L, Terr AI, Adkinson NF, Bochner BS, Burks AW, Holgate S, Lemanske RF, O'Hehir RE. Unconventional Theories and Unproven Methods in Allergy. Middleton's Allergy: Principles and Practice. 2014;1616-35.

    Not in our library

  169. 169.

    GlaxoSmithKline. ENGERIX-B Package Insert. Mississauga, Ontario, Canada. 2013.Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf. Accessed Aug 2016.

    Not in our library

  170. 170.

    Merck & Co. I. RECOMBIVAX HB Package Insert. Merck, Inc. Kenilworth, NJ USA. 2014.Also, https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf. Accessed Aug 2016.

    Not in our library

  171. 171.

    Merck & Co. I. GARDASIL Package Insert. Merck, Inc. Kenilworth, NJ USA. 2011.Also,http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf. Accessed August 2016.

    Not in our library

  172. 172.

    DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J, Team VAERS. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006;24(6):703-7.

    Not in our library10.1016/j.vaccine.2005.07.069

  173. 173.

    Anonymous, Atkinson WL, Wolfe S, Hmborsky J. Latex in Vaccine Packaging. Epidemiology and Prevention of Vaccine-Preventable Diseases. 2012.

    Not in our library

  174. 174.

    Yunginger JW, Jones RT, Fransway AF, Kelso JM, Warner MA, Hunt LW. Extractable latex allergens and proteins in disposable medical gloves and other rubber products. J Allergy Clin Immunol. 1994;93(5):836-42.

    Not in our library10.1016/0091-6749(94)90374-3

  175. 175.

    Hamilton RG, Brown RH, Veltri MA, Feroli ER, Primeau MN, Schauble JF, et al. Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures. Am J Health Syst Pharm. 2005;62(17):1822-7.

    Not in our library10.2146/ajhp050021

  176. 176.

    Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-6.

    Not in our library10.1136/bmj.323.7308.334

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.